» Articles » PMID: 25780299

Corticosteroid Therapy in Ulcerative Colitis: Clinical Response and Predictors

Overview
Specialty Gastroenterology
Date 2015 Mar 18
PMID 25780299
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

Aim: To evaluate clinical response to initial corticosteroid (CS) treatment in Chinese ulcerative colitis patients (UC) and identify predictors of clinical response.

Methods: Four hundred and twenty-three UC patients who were initially treated with oral or intravenous CS from 2007 to 2011 were retrospectively reviewed at eight inflammatory bowel disease centers in China, and 101 consecutive cases with one-year follow-up were analyzed further for clinical response and predictors. Short-term outcomes within one month were classified as primary response and primary non-response. Long-term outcomes within one year were classified as prolonged CS response, CS dependence and secondary non-response. CS refractoriness included primary and secondary non-response. Multivariate analyses were performed to identify predictors associated with clinical response.

Results: Within one month, 95.0% and 5.0% of the cases were classified into primary response and non-response, respectively. Within one year, 41.6% of cases were assessed as prolonged CS response, while 49.5% as CS dependence and 4.0% as secondary non-response. The rate of CS refractoriness was 8.9%, while the cumulative rate of surgery was 6.9% within one year. After multivariate analysis of all the variables, tenesmus was found to be a negative predictor of CS dependence (OR = 0.336; 95%CI: 0.147-0.768; P = 0.013) and weight loss as a predictor of CS refractoriness (OR = 5.662; 95%CI: 1.111-28.857; P = 0.040). After one-month treatment, sustained high Sutherland score (≥ 6) also predicted CS dependence (OR = 2.347; 95%CI: 0.935-5.890; P = 0.014).

Conclusion: Tenesmus was a negative predictor of CS dependence, while weight loss and sustained high Sutherland score were strongly associated with poor CS response.

Citing Articles

Symptoms of anxiety and depression associated with steroid efficacy and clinical outcomes in patients with inflammatory bowel disease.

Duan S, Yang Y, Cao Y, Chen P, Liang C, Zhang Y Front Psychiatry. 2023; 14:1029467.

PMID: 37547213 PMC: 10400767. DOI: 10.3389/fpsyt.2023.1029467.


Chitosan functionalized MnO nanoparticles counteracts ulcerative colitis in mice through modulation of cellular redox state.

Mondal S, Das M, Ghosh R, Singh M, Adhikari A, Darbar S Commun Biol. 2023; 6(1):647.

PMID: 37328528 PMC: 10275949. DOI: 10.1038/s42003-023-05023-6.


Precision medicine and drug optimization in adult inflammatory bowel disease patients.

Vieujean S, Louis E Therap Adv Gastroenterol. 2023; 16:17562848231173331.

PMID: 37197397 PMC: 10184262. DOI: 10.1177/17562848231173331.


Current evidence and clinical relevance of drug-microbiota interactions in inflammatory bowel disease.

Becker H, Demers K, Derijks L, Jonkers D, Penders J Front Microbiol. 2023; 14:1107976.

PMID: 36910207 PMC: 9996055. DOI: 10.3389/fmicb.2023.1107976.


Enteric-Coated Cologrit Tablet Exhibit Robust Anti-Inflammatory Response in Ulcerative Colitis-like In-Vitro Models by Attuning NFκB-Centric Signaling Axis.

Balkrishna A, Singh R, Gohel V, Arora S, Dev R, Bhattacharya K Pharmaceuticals (Basel). 2023; 16(1).

PMID: 36678560 PMC: 9862254. DOI: 10.3390/ph16010063.


References
1.
Tung J, Loftus Jr E, Freese D, El-Youssef M, Zinsmeister A, Melton 3rd L . A population-based study of the frequency of corticosteroid resistance and dependence in pediatric patients with Crohn's disease and ulcerative colitis. Inflamm Bowel Dis. 2006; 12(12):1093-100. DOI: 10.1097/01.mib.0000235835.32176.85. View

2.
Moss A, Farrell R . Infliximab for induction and maintenance therapy for ulcerative colitis. Gastroenterology. 2006; 131(5):1649-51. DOI: 10.1053/j.gastro.2006.09.039. View

3.
Mack D, Langton C, Markowitz J, LeLeiko N, Griffiths A, Bousvaros A . Laboratory values for children with newly diagnosed inflammatory bowel disease. Pediatrics. 2007; 119(6):1113-9. DOI: 10.1542/peds.2006-1865. View

4.
Wang Y, Zhang H, OuYang Q . Clinical manifestations of inflammatory bowel disease: East and West differences. J Dig Dis. 2007; 8(3):121-7. DOI: 10.1111/j.1443-9573.2007.00296.x. View

5.
Wang Y, OuYang Q . Ulcerative colitis in China: retrospective analysis of 3100 hospitalized patients. J Gastroenterol Hepatol. 2007; 22(9):1450-5. DOI: 10.1111/j.1440-1746.2007.04873.x. View